A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2

Majdoubi, Abdelilah; Michalski, Christina; O’Connell, Sarah E.; Dada, Sarah; Narpala, Sandeep; Gelinas, Jean; Mehta, Disha; Cheung, Claire; Winkler, Dirk F.H.; Basappa, Manjula; Liu, Aaron C.; Görges, Matthias; Barakauskas, Vilte E.; Irvine, Mike; Mehalko, Jennifer; Esposito, Dominic; Sekirov, Inna; Jassem, Agatha N.; Goldfarb, David M.; Pelech, Steven; Douek, Daniel C.; McDermott, Adrian B.; Lavoie, Pascal M.

Preexisting cross-reactivity to SARS-CoV-2 occurs in the absence of prior viral exposure. However, this has been difficult to quantify at the population level due to a lack of reliably defined seroreactivity thresholds. Using an orthogonal antibody testing approach, we estimated that about 0.6% of nontriaged adults from the greater Vancouver, Canada, area between May 17 and June 19, 2020, showed clear evidence of a prior SARS-CoV-2 infection, after adjusting for false-positive and false-negative test results. Using a highly sensitive multiplex assay and positive/negative thresholds established in infants in whom maternal antibodies have waned, we determined that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2. This seroreactivity was evenly distributed across age and sex, correlated with circulating coronaviruses’ reactivity, and was partially outcompeted by soluble circulating coronaviruses’ spike. Using a custom SARS-CoV-2 peptide mapping array, we found that this antibody reactivity broadly mapped to spike and to conserved nonstructural viral proteins. We conclude that most adults display preexisting antibody cross-reactivity against SARS-CoV-2, which further supports investigation of how this may impact the clinical severity of COVID-19 or SARS-CoV-2 vaccine responses.